[Endocrinology: what's new in 2023].
| Autor: | Ameti A; Service d'endocrinologie, diabétologie et métabolisme, Centre hospitalier universitaire vaudois, 1011 Lausanne., Chouchane K; Service d'endocrinologie, diabétologie et métabolisme, Centre hospitalier universitaire vaudois, 1011 Lausanne., Fontana E; Service de diabétologie-endocrinologie, HFR Fribourg, Hôpital cantonal, 1752 Villars-sur-Glâne., Papadakis GE; Service d'endocrinologie, diabétologie et métabolisme, Centre hospitalier universitaire vaudois, 1011 Lausanne. |
|---|---|
| Jazyk: | francouzština |
| Zdroj: | Revue medicale suisse [Rev Med Suisse] 2024 Jan 17; Vol. 20 (856-7), pp. 36-41. |
| DOI: | 10.53738/REVMED.2024.20.856-7.36 |
| Abstrakt: | This overview provides a selection of studies published in 2023 with an impact on clinical practice. In reproductive endocrinology, important studies have addressed fertility preservation in men with Klinefelter's syndrome, the cardiovascular safety of testosterone replacement therapy, and a novel therapy, fezolinetant, for vasomotor symptoms of menopause. The updated European recommendations concerning adrenal incidentalomas will considerably modify current clinical practice. Based on a solid epidemiological work, the prevalence of pituitary adenomas has been confirmed to affect about 1 per 1000 individuals. Finally, a large British study allows to refine the benefit-risk profile of the three options available for the treatment of hyperthyroidism. Competing Interests: Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|